製品番号: HY-112288

C188-9

(別名: TTI-101)

35 Cited Publications

カスタマーレビュー

Based on 35 publication(s) in Google Scholar

C188-9 (TTI-101) is a STAT3 inhibitor with a K_d value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.75%
CAS 番号: 432001-19-9
分子式: C₂₇H₂₁NO₅S
分子量:471.52

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

C188-9 構造式

CAS 番号: 432001-19-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- Parmacokinetics
- 体内実験
- 臨床実験
化学情報
Publications (35)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

STAT3

4.7 nM (Kd)

STAT1

DNMT1

STAT アイソフォーム固有の製品をすべて表示 :

DNA Methyltransferase アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
AGS	IC₅₀	9.99 μM Compound: TTI-101; C188-9, 1	Antiproliferative activity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35944386]
GDM-1	EC₅₀	6 μM Compound: 54; C188-9	Induction of apoptosis in human GDM-1 cells incubated for 48 hrs by Annexin V staining assay Induction of apoptosis in human GDM-1 cells incubated for 48 hrs by Annexin V staining assay	[PMID: 31810784]
Kasumi 1	EC₅₀	8 μM Compound: 54; C188-9	Induction of apoptosis in human Kasumi 1 cells incubated for 48 hrs by Annexin V staining assay Induction of apoptosis in human Kasumi 1 cells incubated for 48 hrs by Annexin V staining assay	[PMID: 31810784]
MCF7	EC₅₀	13.75 μM Compound: C188-9	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CyQuant assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CyQuant assay	[PMID: 33352047]
MDA-MB-231	EC₅₀	25.7 μM Compound: C188-9	Antiproliferative activity against human MDA-MB-231 cells harbouring STAT3 assessed as reduction in cell viability at upto 10 uM incubated for 72 hrs by CyQuant assay Antiproliferative activity against human MDA-MB-231 cells harbouring STAT3 assessed as reduction in cell viability at upto 10 uM incubated for 72 hrs by CyQuant assay	[PMID: 33352047]
MGC-803	IC₅₀	3.26 μM Compound: TTI-101; C188-9, 1	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35944386]
MKN-1	IC₅₀	10.21 μM Compound: TTI-101; C188-9, 1	Antiproliferative activity against human MKN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MKN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35944386]
MKN-28	IC₅₀	40.01 μM Compound: TTI-101; C188-9, 1	Antiproliferative activity against human MKN-28 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MKN-28 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35944386]

体外実験

C188-9 (0.1-1000 μM) potently inhibits the binding of recombinant STAT3 to its pY peptide ligand, with a calculated K_i of 12.4 nM^[1].
C188-9 binds directly to STAT3 with high affinity, with a K_d value of 4.7 nM^[1].
C188-9 (1-300 μM; 1 h) inhibits ligand-activated pSTAT3 (IC₅₀ 8.9 μM) and pSTAT1 (IC₅₀ 9.5 μM) in Kasumi-1 cells^[1].
C188-9 (48 h) potently inhibits the anchorage-dependent growth of UM-SCC-17B head and neck squamous cell carcinoma cells, with an IC₅₀ of 3.2 μM after 48 hours of treatment^[1].
C188-9 (72 h) inhibits the anchorage-independent growth of head and neck squamous cell carcinoma cells including SCC-35, SCC-61, UM-SCC-17B and HN30. After 72 hours of treatment, its IC₅₀ values range from 0.7 to 14.8 μM depending on the cell line^[1].
C188-9 (10 µM) acts synergistically with 1 µM DAC to potently inhibit the proliferation of pancreatic cancer cells BxPC-3 and PANC-1, and this effect is superior to that of high-dose DAC monotherapy^[2].
Pretreatment of differentiated C2C12 mouse skeletal muscle myotubes with C188-9 (10 µM; 1 h) alleviates LPS-induced myotube atrophy by inhibiting the activation of STAT3 and the ubiquitin-proteasome pathway^[3].
C188-9 (24-72 h) inhibits both anchorage-dependent and anchorage-independent proliferation of all tested non-small cell lung cancer (NSCLC) cell lines, with IC₅₀ values ranging from 3.06 to 52.44 μM^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[4]

Cell Line:

A549 (human NSCLC cell line)
Concentration:

No specific explanation
Incubation Time:

24 h, 48 h
Result:

Increased the percentage of apoptotic A549 cells from 3.25-3.5% in untreated cells to 11.75% after 24 h incubation, and to 82.7% after 48 h incubation.

Parmacokinetics

Species	Dose	Route	AUC_0-∞	Plasma Concentration
Mice^[1]	10 mg/kg	i.p.	12.5 μg·h/mL	1.9 mg/mL
Mice^[1]	10 mg/kg	p.o.	12.5 μg·h/mL	/

体内実験

C188-9 (100 mg/kg; intraperitoneal injection; 5 times per week) inhibits the growth of UM-SCC-17B xenograft tumors by reducing the levels of pSTAT3 and pSTAT1 in tumors^[1].
C188-9 (100 mg/kg; i.p.; once daily; for 4 consecutive weeks) inhibits orthotopic pancreatic tumor growth in nude mice, reduces the proliferative capacity of tumor cells, decreases the formation of metastatic nodules, regulates epithelial-mesenchymal transition markers, upregulates RASSF1A expression and downregulates DNMT1 expression, without inducing significant body weight loss or hematological toxicity^[2].
C188-9 (50 mg/kg; i.p.) inhibits the activation of STAT3 and the ubiquitin-proteasome pathway, ameliorates sepsis-related skeletal muscle wasting and myasthenia symptoms in mice, and does not affect the autophagy pathway^[3].
C188-9 (i.p., 50 mg/kg, twice daily for 3 weeks) inhibits NSCLC tumor growth in athymic nude mice, reduces tumor weight by 50%, decreases tumor pSTAT3 levels by 65%, and lowers PBMC pSTAT3 levels by 25%^[4].
C188-9 (i.p.; daily; for 14 consecutive days at a dose of 12.5 mg/kg) inhibits cancer cachexia in C26 tumor-bearing CD2F1 mice by suppressing the Stat3 signaling pathway, preserving muscle mass, improving muscle function, normalizing protein turnover, and blocking caspase-3- and ubiquitin-proteasome system-mediated proteolysis^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic nude mice (male, 8-10 weeks old)^[1]
Dosage:

100 mg/kg
Administration:

i.p.; 5 times per week
Result:

Reduced UM-SCC-17B xenograft growth with statistically significant difference compared to control (p=0.027).
Reduced tumor levels of pSTAT3 by 57% compared to control (p=0.017).
Reduced tumor levels of pSTAT1 by 80% compared to control (p=0.000003).
Altered the expression of 384 total genes in tumors, including 76 STAT3-regulated genes and 40 STAT1-regulated genes.

Animal Model:

nude mice (5-week-old, female)^[2]
Dosage:

100 mg/kg
Administration:

i.p.; once daily; 4 weeks
Result:

Reduced tumor volume relative to control group.
Did not induce significant changes in mouse body weight or white blood cell counts relative to control group.
Reduced tumor cell proliferation (Ki-67 staining) relative to control group.
Lowered number of metastatic nodules relative to control group.
Increased E-cadherin expression in tumor tissue relative to control group.
Reduced Vimentin, N-cadherin, and Snail1 expression in tumor tissue relative to control group.
Elevated RASSF1A protein and mRNA expression in tumor tissue relative to control group.
Reduced DNMT1 protein expression in tumor tissue relative to control group.

Animal Model:

C57BL/6 (male, 8-10 weeks old, 22-26 g)^[3]
Dosage:

50 mg/kg
Administration:

i.p.
Result:

Did not affect acute-phase mortality or appetite loss.
Significantly reversed sepsis-induced tibialis anterior (TA) muscle atrophy.
Restored forelimb grip strength.
Reduced the murine sepsis score at 1 and 3 days post-treatment.
Rescued sepsis-induced TA muscle fiber shrinkage via immunofluorescence staining.
Suppressed sepsis-induced activation of phosphorylated STAT3 (Tyr705) and downstream ubiquitin ligase proteins atrogin-1/MAFbx and MuRF1 in TA muscles.
Did not alter plasma or muscle IL-6/TNF-α levels, or autophagy pathway markers (LC3B-II/LC3B-I ratio, LC3B puncta).

Animal Model:

CD2F1 (female, 8-10 weeks of age, subcutaneous inoculation of isogenic C26 colon carcinoma cells)^[6]
Dosage:

12.5 mg/kg
Administration:

i.p.; daily; 14 days
Result:

Suppressed muscle p-Stat3 activation, and reduced muscle expression of C/EBP-δ and myostatin.
Increased body weight relative to diluent-treated tumor-bearing mice, and preserved mass of tibialis anterior, extensor digitorum longus, gastrocnemius, and soleus muscles.
Maintained myofiber size distribution similar to non-tumor-bearing control mice.
Improved muscle grip strength.
Increased protein synthesis in soleus and extensor digitorum longus muscles.
Decreased protein degradation in soleus and extensor digitorum longus muscles.
Blocked the tumor-induced increase in 14-kDa actin fragment (a marker of caspase-3-mediated proteolysis).
Reduced tumor-induced elevations in muscle MAFbx/Atrogin-1 and MuRF-1 mRNA and protein levels.
Suppressed tumor-induced increases in proteasome activity.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 432001-19-9
性状 Solid
分子量 471.52
分子式 C₂₇H₂₁NO₅S
Color Light brown to gray
SMILES

O=S(C1=CC=C(OC)C=C1)(NC2=C3C=CC=CC3=C(O)C(C4=C5C=CC=CC5=CC=C4O)=C2)=O
別名

TTI-101
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (35)

All WBCell Proliferation/Viability AssayRT-PCRIn Vivo Efficacy StudyHistological Imaging/StainingCell Imaging/Staining

Sort by:

Journal Impact Factor

Cell Metab

Adipo-glial signaling mediates metabolic adaptation in peripheral nerve regeneration. [Abstract]

2023 Dec 5;35(12):2136-2152.e9. PMID: 37989315
Nat Commun

Osteocytes directly regulate osteolysis via MYD88 signaling in bacterial bone infection. [Abstract]

2022 Nov 4;13(1):6648. PMID: 36333322
Bone Res

The HOXC10/NOD1/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer. [Abstract]

2024 Aug 27;12(1):47. PMID: 39191757
Acta Pharm Sin B

Dimeric natural product panepocyclinol A inhibits STAT3 via di-covalent modification. [Abstract]

2025 Jan;15(1):409-423. PMID: 40041920

C188-9 purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Jan;15(1):409-423. [Abstract]

Karpas299 cells were treated with C188-9 (5, 20 μM) for 4 h. STAT3 and p-STAT3 were analyzed by Western blotting.
J Exp Clin Cancer Res

A novel circular RNA circ-LRIG3 facilitates the malignant progression of hepatocellular carcinoma by modulating the EZH2/STAT3 signaling. [Abstract]

2020 Nov 23;39(1):252. PMID: 33222697

C188-9 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2020 Nov 23;39(1):252. [Abstract]

CCK-8 and Transwell assays detecting the cell viability and invasion in circ-LRIG3-overexpressing HepG2 cells treated with C188–9.

C188-9 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2020 Nov 23;39(1):252. [Abstract]

qRT-PCR analysis of circ-LRIG3 in HepG2 and SMMC-7721 cells treated with colivelin and C188–9.

C188-9 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2020 Nov 23;39(1):252. [Abstract]

The image, volume weight of mice bearing tumors of circ-LRIG3-overexpressing cells treated with C188–9 (50 mg/kg, i.p.).

C188-9 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2020 Nov 23;39(1):252. [Abstract]

H&E and IHC staining in tumor tissues of nude mice treated with C188–9 treated with C188–9 (50 mg/kg, i.p.).

C188-9 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2020 Nov 23;39(1):252. [Abstract]

TUNEL staining in tumor tissues of nude mice treated with C188–9 treated with C188–9 (50 mg/kg, i.p.).
Cell Death Dis

BRUCE liver-KO enhances MASLD/MASH development in the steatotic PTEN-KO background by impairing mitochondrial metabolism and activating STAT3. [Abstract]

2025 Dec 11. PMID: 41381438
Cell Death Dis

MCM7 promotes liver fibrosis by transcriptionally regulating IL11 via the SHCBP1-RACGAP1-STAT3 axis. [Abstract]

2025 Aug 11;16(1):608. PMID: 40789837
Cell Death Dis

Inhibition of Rho GEFs attenuates pulmonary fibrosis through suppressing myofibroblast activation and reprogramming profibrotic macrophages. [Abstract]

2025 Apr 11;16(1):278. PMID: 40216763
Phytomedicine

6''-O-acetylsaikosaponin D targets STAT3-mediated transcriptional remodeling to induce ferroptosis and apoptosis. [Abstract]

2026 May 15:157:158301. PMID: 42166974
Phytomedicine

Epigallocatechin gallate suppresses mitotic clonal expansion and adipogenic differentiation of preadipocytes through impeding JAK2/STAT3-mediated transcriptional cascades. [Abstract]

2024 Jul:129:155563. PMID: 38552377
Free Radic Biol Med

MTH1 suppression enhances the stemness of MCF7 through upregulation of STAT3. [Abstract]

2022 Aug 1:188:447-458. PMID: 35809767
Br J Pharmacol

A novel synthesised STAT3 inhibitor exerts potent anti-tumour activity by inducing lysosome-dependent cell death. [Abstract]

2025 May 13. PMID: 40356419
J Transl Med

Siramesine induced cell death of glioblastoma through inactivating the STAT3-MGMT signaling pathway. [Abstract]

2025 Jul 10;23(1):780. PMID: 40640878
Cell Rep

Gasdermin C reprograms metabolism through the CAMKK2-AMPK axis to promote lung adenocarcinoma progression and radioresistance. [Abstract]

2026 May 22;45(6):117427. PMID: 42176271
Cell Rep

A MYC-STAMBPL1-TOE1 positive feedback loop mediates EGFR stability in hepatocellular carcinoma. [Abstract]

2024 Oct 8;43(10):114812. PMID: 39388352
Ecotoxicol Environ Saf

Clusterin inhibits Cr(VI)-induced apoptosis via enhancing mitochondrial biogenesis through AKT-associated STAT3 activation in L02 hepatocytes. [Abstract]

2021 Sep 15:221:112447. PMID: 34175824
Cancer Cell Int

TTI-101 targets STAT3/c-Myc signaling pathway to suppress cervical cancer progression: an integrated experimental and computational analysis. [Abstract]

2024 Aug 12;24(1):286. PMID: 39135042
Cancer Cell Int

Identification of glycolysis related pathways in pancreatic adenocarcinoma and liver hepatocellular carcinoma based on TCGA and GEO datasets. [Abstract]

2021 Feb 19;21(1):128. PMID: 33607990
Front Immunol

Interleukin-22 From Type 3 Innate Lymphoid Cells Aggravates Lupus Nephritis by Promoting Macrophage Infiltration in Lupus-Prone Mice. [Abstract]

2021 Feb 26;12:584414. PMID: 33717066
Int J Mol Sci

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia. [Abstract]

2022 Oct 20;23(20):12587. PMID: 36293442
Biomolecules

DB-2B, a Novel and Selective STAT3 Inhibitor Inhibits Colorectal Cancer Progression In Vitro and In Vivo. [Abstract]

2026 May 20;16(5):752. PMID: 42194100
Mol Oncol

The STAT3-miR-223-TGFBR3/HMGCS1 axis modulates the progression of cervical carcinoma. [Abstract]

2020 Sep;14(9):2313-2331. PMID: 32491253
J Biol Chem

STAT3 activation of SCAP-SREBP-1 signaling upregulates fatty acid synthesis to promote tumor growth. [Abstract]

2024 Jun;300(6):107351. PMID: 38718868
Biomedicines

LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells. [Abstract]

2022 Aug 18;10(8):2003. PMID: 36009550
J Virol

Role of Src family kinases Fyn and Lyn in arenavirus infection. [Abstract]

2026 Apr 21;100(4):e0024126. PMID: 41914886
Clin Exp Metastasis

Tumor microenvironment dynamics in oral cancer: unveiling the role of inflammatory cytokines in a syngeneic mouse model. [Abstract]

2024 Dec;41(6):891-908. PMID: 39126553
Toxicol Lett

Hepatocytic AP-1 and STAT3 contribute to chemotaxis in alphanaphthylisothiocyanate-induced cholestatic liver injury. [Abstract]

2023 Jan 15:373:184-193. PMID: 36460194
Infect Immun

TRP75-mediated STAT3 activation promotes anti-apoptotic signaling and Ehrlichia chaffeensis infection. [Abstract]

2025 Oct 20:e0045925. PMID: 41115066
Eur J Haematol

Interferon gamma regulates a complex pro-survival signal network in chronic lymphocytic leukemia. [Abstract]

2023 Apr;110(4):435-443. PMID: 36576398
Leuk Lymphoma

IFN-γ enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway. [Abstract]

2023 Jan;64(1):71-78. PMID: 36222521
Int J Med Microbiol

LincRNA-Cox2 regulates IL6/JAK3/STAT3 and NF-κB P65 pathway activation in Listeria monocytogenes-infected RAW264.7 cells. [Abstract]

2021 Jul;311(5):151515. PMID: 34146956
bioRxiv

2026 Feb 20.
Patent

US20250144054A1.
bioRxiv

BRUCE liver-deficiency potentiates MASLD/MASH in PTEN liver-deficient background by impairment of mitochondrial metabolism in hepatocytes and activation of STAT3 signaling in hepatic stellate cells. [Abstract]

2024 Sep 14:2024.09.13.611500. PMID: 39314445
Ann Transl Med

Stromal cells promote chemoresistance of acute myeloid leukemia cells via activation of the IL-6/STAT3/OXPHOS axis. [Abstract]

2020 Nov;8(21):1346. PMID: 33313091

溶剤 & 溶解度

体外:

DMSO : 25 mg/mL (53.02 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1208 mL

10.6040 mL

21.2080 mL

5 mM

0.4242 mL

2.1208 mL

4.2416 mL

10 mM

0.2121 mL

1.0604 mL

2.1208 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (292 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Bharadwaj U, et al. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2016;7(18):26307-26330. [Content Brief]

[2]. Kong R, et al. Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2'-Deoxycytidine Against Pancreatic Cancer. Front Oncol. 2020;10:612. Published 2020 May 8. [Content Brief]

[3]. Ono Y, et al. Sepsis-associated skeletal muscle wasting is ameliorated by pharmacological inhibition of the STAT3 signaling pathway in mice. Sci Rep. 2026;16(1):5008. Published 2026 Jan 11. [Content Brief]

[4]. Lewis KM, et al. Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer. Lung Cancer. 2015 Nov;90(2):182-90. [Content Brief]

[5]. Redell MS, et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117(21):5701-5709. [Content Brief]

[6]. Silva KA, et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem. 2015;290(17):11177-11187. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1208 mL	10.6040 mL	21.2080 mL	53.0200 mL
	5 mM	0.4242 mL	2.1208 mL	4.2416 mL	10.6040 mL
	10 mM	0.2121 mL	1.0604 mL	2.1208 mL	5.3020 mL
	15 mM	0.1414 mL	0.7069 mL	1.4139 mL	3.5347 mL
	20 mM	0.1060 mL	0.5302 mL	1.0604 mL	2.6510 mL
	25 mM	0.0848 mL	0.4242 mL	0.8483 mL	2.1208 mL
	30 mM	0.0707 mL	0.3535 mL	0.7069 mL	1.7673 mL
	40 mM	0.0530 mL	0.2651 mL	0.5302 mL	1.3255 mL
	50 mM	0.0424 mL	0.2121 mL	0.4242 mL	1.0604 mL

C188-9

35 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

C188-9

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Cell Death Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 C188-9

STAT アイソフォーム固有の製品をすべて表示

DNA Methyltransferase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (35)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

C188-9 関連分類

HY-112288 関連分類